All episodes
LCC in Japanese: ASCO 2025 Highlights
Preview: IASLC | ASCO 2025 North American Conference on Lung Cancer
FDA Approval: Datopotamab Deruxtecan for EGFR NSCLC
FDA Approval: Sunvozertinib for EGFR Exon 20
LCC in Portuguese: Virtual Tumor Board - EGFR NSCLC
IASLC_WCLC 2025 Preview
Virtual Tumor Board: Resectable EGFR NSCLC
FDA Approval: Taletrectinib and ROS1 NSCLC
IASLC - ASCO 2025 Highlights
FDA Approval: Telisotuzumab Vedotin and MET-Positive NSCLC
LCC in Korean: Lung Cancer Updates & Future Directions
Global Advances and Persistent Disparities in Lung Cancer Treatment
Dr. Bryant Lin Teaching My Cancer
AACR 2025 Highlights
What You Should Know About RET-Positive NSCLC: Live from TexasLung25
Excuse me, What? Top Recommendations for Effective Patient Communication: Live from TexasLung25
ELCC 2025 Highlights: Insights and Review of the Data
LCC in Korean: 2024 Lung Cancer Updates
Virtual Tumor Board: Targeting Residual Disease
LCC in Mandarin: Virtual Tumor Board - EGFR NSCLC
LCC in Italian: Virtual Tumor Board - Resectable NSCLC
The Microbiome and Immunotherapy for Lung Cancer
Thymus Talk: Unraveling Thymoma and Thymic Carcinoma
Lung Cancer Considered in Turkish: First-Line Therapies in EGFR Mutant NSCLC
Live from TTLC25: Lung Cancer and Brain Metastasis
Lung Cancer Considered in Hungarian: Lung Cancer Treatment Updates
LCC in Cantonese: WCLC24 Highlights
Virtual Tumor Board: Stage III ALK+ NSCLC
Live from TTLC25: Targeted Therapy in Early Stage NSCLC Debate
The Benefits of Patient Advocacy Groups
Live from TTLC25: Targeted Therapy in SCLC
Live from TTLC 2025: Mesothelioma and NUT Carcinoma
LCC in Arabic: Chemo Immunotherapy in Metastatic NSCLC
Virtual Tumor Board: Treating EGFR NSCLC After TKI Resistance
LAURA Study (Part 2) - Radiation Oncology Perspective
Lung Cancer in Mexico: Perspectives from the North and Ciudad de Mexico
IASLC Lung Cancer Considered in German
FDA Approval Zenocutuzumab For NRG1 Fusion Cancers
ESMO Immuno-Oncology Congress 2024 Highlights
2025 Pan-Africa Conference on Lung Cancer Meeting Preview
IASLC Lung Cancer Considered: ESMO Asia 2024 Highlights
FDA Approval: TT Fields for NSCLC
FDA Approval: Perioperative Nivolumab + Chemotherapy - CheckMate 77T
LALCA Episode in English
Lung Cancer Considered in German
Ninth Edition of Tumor, Node and Metastasis (TNM) Classification System
LAURA Trial Part 1
LALCA Highlights in Spanish
Lung Cancer Considered--The Year in Review
Virtual Tumor Board_Metastatic Squamous NSCLC
LCC in Hindi: Contemporary Issues in Lung Cancer Care
Virtual Tumor Board: Pregnancy
IASLC - Exercise And Lung Cancer
IASLC - Hot Topic Meeting On Tolerance And Resistance To Targeted Therapy In NSCLC 2
LCC in Arabic: Training and Education in Medical Oncology and Lung Cancer
IASLC Virtual Tumor Board Relapsed SCLC
Lung Cancer Considered--Managing ADC Toxicities
LCC in Arabic: WCLC 2024 Highlights
IASLC LALCA Preview (in Spanish)
ESMO 2024 Highlights
FDA Approval: KEYNOTE 483, Pembrolizumab plus Chemotherapy for Mesothelioma
IASLC - ACLC 2024 Preview
FDA Approval: MARIPOSA2, Amivantamab plus Chemotherapy after Osimertinib for EGFR NSCLC
LCC in Portuguese: WCLC 2024 Highlights
Live From WCLC 2024: Nurse Practitioner Highlights
LCC in Spanish: WCLC 2024 Highlights
Live From WCLC 2024: Meeting Summary
LCC in Mandarin: WCLC 2024 Highlights
Live From WCLC 2024: Monday Highlights
LCC in Korean: WCLC 2024 Highlights
Live From WCLC 2024: Sunday Highlights
With Eyes On The Future IASLC 50th Anniversary
IASLC's 50th Anniversary: The IASLC Today
IASLC - The First Decade
FDA Approval: MARIPOSA, First-Line Amivantamab plus Lazertinib for EGFR NSCLC
LCC In Mandarin
IASLC - WCLC 2024 Preview
IASLC - Spanish Episode Neoadjuvant Therapies In NSCLC
Seminal Trial Series: Crizotinib in PROFILE 1001
Lung Cancer Considered in Farsi
LCC In Greek
IASLC - Immunotherapy In Driver - Positive NSCLC
Clinical Discussion in the Management of Early-Stage NSCLC
LCC: The Management Of CNS Metastases In Driver Negative NSCLC
Lung Cancer Considered in Romanian
The Importance of Waiting for Biomarker Results in NSCLC
LCC In Italian--First-Line Treatment Options for EGFR Mutant NSCLC
FDA Approval Of Tarlartamab
ASCO 2024 Summary Part 2
IASLC - ASCO 2024 Summary--Part 1
Updates in CT Screening for Lung Cancer
LCC and Smoking Cessation
LCC in French Canadian
Virtual Tumor Board: PD-L1 Low NSCLC
When two worlds collide: Adenosquamous histology
KRAS in NSCLC: Beyond G12C
FDA Approval: Adjuvant Alectinib for Resected NSCLC
IASLC DEI Initiative Global Member Survey
FDA Approval: FLAURA2, First Line Osimertinib Plus Chemotherapy for EGFR NSCLC
ELCC 2024 Highlights